Use of L. reuteri for recovery of microbiota dysbiosis in early life

Inventors

Garcia-Rodenas, Clara Lucia • Berger, Bernard • Ngom-Bru, Catherine • LePage, Melissa • NEVILLE, Tara

Assignees

Biogaia AB

Abstract

The invention concerns Lactobacillus reuteri for use in the prevention or treatment of microbiota dysbiosis, in particular, decreased levels of Actinobacteria and increased levels of Proteobacteria, in young mammals and in the prevention or treatment of disorders associated therewith. The microbiota dysbiosis may have been cause by numerous factors including being born by caesarean section, exposure to antibiotics in utero or after birth, or, parenteral feeding, hospitalizing, psychological stress or by gastrointestinal dysfunctions. The disorders that may be treated or prevented by preventing or treating microbiota dysbiosis include propensity to infection, allergy, type I diabetes mellitus, insulin resistance, type 2 diabetes, celiac disease, peripheral and central adiposity, obesity, necrotizing enterocolitis, inflammatory bowel disease, such as Crohn's disease and ulcerative colitis, and functional gastrointestinal disorders such as IBS, functional diarrhea, functional constipation, recurrent abdominal pain, and dyspepsia.

Core Innovation

The invention concerns a method for treatment or reducing a risk of one or more disorders selected from the group consisting of propensity insulin resistance, type 2 diabetes, peripheral and central adiposity, and obesity. The disorders are associated with microbiota dysbiosis occurring in a young human aged up to three years of age, and the disorders occur in the young human or later in the life of the young human. The method includes administering a combination of Lactobacillus reuteri and one or more additional probiotics to the young human, where the administering is effective to treat the microbiota dysbiosis.

The described dysbiosis is characterized by decreased Actinobacteria, including Bifidobacterium, and increased Proteobacteria, including potentially pathogenic genera. The document describes risk factors for early-life microbiota dysbiosis including caesarean delivery, antibiotic exposure, preterm birth, parenteral feeding, hospitalization and stress, and gastrointestinal dysfunctions. The invention is positioned as a way to promote recovery from this dysbiosis in young mammals, including young humans.

The document provides rationale and scope for Lactobacillus reuteri administration, including strain DSM 17938, and describes an observed association with restoration of a normal vaginal-delivery-like microbiota profile in caesarean-delivered infants. Example results are described showing restoration of Actinobacteria and reduction of Proteobacteria, together with normalization of key taxa at two weeks, and improved recovery at four months. The text also lists disorder types connected to dysbiosis, including infection propensity, allergy, type 1 diabetes, insulin resistance and type 2 diabetes, celiac disease, adiposity and obesity, necrotizing enterocolitis, inflammatory bowel disease, and IBS-like functional gastrointestinal disorders.

Claims Coverage

The partial content includes one independent claim. It covers a treatment and risk-reduction method for selected disorders linked to microbiota dysbiosis in young humans, using a combination of Lactobacillus reuteri and additional probiotics, with administering effective to treat the microbiota dysbiosis.

Independent claim defines treatment or risk reduction for selected dysbiosis-associated disorders in young humans up to three years old (and disorders occurring in the young human or later in life) by administering an effective combination of Lactobacillus reuteri with one or more additional probiotics to treat the microbiota dysbiosis.

Stated Advantages

Documented Applications

No documented applications found